Art. -Nr.: HY-14541

Olanzapine

(Synonyms: LY170053)

14 Cited Publications

Kundenbewertung

Based on 14 publication(s) in Google Scholar

Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (K_i=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (K_i=11 to 31 nM), muscarinic M1-5 (K_i=1.9-25 nM), and adrenergic α1 receptor (K_i=19 nM). Olanzapine is an atypical antipsychotic.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.96%
CAS. Nr.: 132539-06-1
Formel: C₁₇H₂₀N₄S
Molecular Weight:312.44

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Olanzapine Chemical Structure

CAS. Nr.: 132539-06-1

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (14)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

5-HT_2A Receptor

4 nM (Ki)

5-HT_2A Receptor

5-HT₆ Receptor

5-HT₁ Receptor

7 nM (Ki)

5-HT₆ Receptor

5 nM (Ki)

5-HT_2C Receptor

11 nM (Ki)

5-HT₃ Receptor

57 nM (Ki)

Adrenergic α1 Receptor

19 nM (Ki)

Muscarinic M1-5 Receptor

1.9-25 nM (Ki)

Dopamine Receptor

Mitophagy

Apoptosis

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen :

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen :

Alle mAChR Isoform-spezifische Produkte anzeigen :

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	0.173 μM Compound: olanzapine	Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells	[PMID: 8831770]
HEK293	IC₅₀	0.1 μM Compound: Olanzapine	Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method	[PMID: 26227779]
RAW264.7	CC₅₀	198.3 μM Compound: Olanzapine	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38283231]
WI-38	CC₅₀	>100 μM Compound: Olanzapine	Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay	[PMID: 17893158]
WI-38	EC₅₀	>100 μM Compound: Olanzapine	Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay	[PMID: 17893158]

In Vitro

Olanzapine binds weakly to GABAA, Benzodiazepine (BZD), and β-adrenergic receptors (K_i>10 μM) ^[1]^[2].
Olanzapine induces autophagy in human SH-SY5Y neuronal cell line^[3].
Olanzapine (1-100 μM for 144 h under serum starvation) results in a marked anti-proliferative effect in glioblastoma cell lines as well as glioma stem-like cells^[4].
Olanzapine also enhances Temozolomide (HY-17364)’s anti-tumor activity in glioblastoma cell lines^[4].
Olanzapine induces apoptosis and necrosis in glioblastoma cell lines^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[4]

Cell Line:

U87MG and A172 glioblastoma cell lines as well as SC38 and SC40 glioma stem-like cells
Concentration:

1, 10, 100 μM
Incubation Time:

144 h; under serum starvation (1.5 % FBS) prior to performing MTT-assays
Result:

Resulted in a marked antiproliferative effect with IC₅₀ values ranging from 25 to 79.9 µM. In U87MG cells, anchorage-independent growth was dose-dependently inhibited. In A172 cells, migration was also shown to be inhibited in a dose-dependent manner.

Western Blot Analysis^[4]

Cell Line:

U87MG and A172 cells
Concentration:

10, 25, 50, and 100 μM
Incubation Time:

7 h, 24 h, 48 h, 72 h
Result:

Led to a dose responsive decrease of pAMPK expression after 72 h of treatment.

In Vivo

Olanzapine (0.75, 1.5 and 3 mg/kg) evaluates body weight and periuterine fat mass, as well as insulin, non-esterified fatty acids, triglycerides, and glucose levels in mice^[5]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Forty-two, 14, and 28 female CD-1 mice ^[5]
Dosage:

0.75, 1.5 and 3 mg/kg
Administration:

Orally and chronically administered; 35 days
Result:

Increased body weight relative to vehicle on days 20-22, and from day 32 onwards there was a straightforward increase in body weight at 3 mg/kg. No differences were found between control and mice administered olanzapine at both 1.5 and 0.75 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 132539-06-1
Appearance Solid
Molecular Weight 312.44
Formel C₁₇H₂₀N₄S
Color Light yellow to yellow
SMILES

CC1=CC(C(N2CCN(C)CC2)=N3)=C(S1)NC4=C3C=CC=C4
Synonyms

LY170053
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (14)

All ELISAWBHistological Imaging/StainingRT-PCRCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nat Commun

Maprotiline restores ER homeostasis and rescues neurodegeneration via Histamine Receptor H1 inhibition in retinal ganglion cells. [Abstract]

2022 Nov 10;13(1):6796. PMID: 36357388

Olanzapine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 10;13(1):6796. [Abstract]

Relative CHOP-Luc activities of individual tested compounds (Olanzapine) at 20 µM in the presence of Tm/Tg (1 µM) relative to DMSO, 24 hours after exposure.
Acta Pharmacol Sin

Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats. [Abstract]

2021 Aug;42(8):1267-1279. PMID: 33976388

Olanzapine purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279. [Abstract]

Olanzapine (Ola: 1.0 mg/kg). Serum insulin-metabolizing hormone levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.

Olanzapine purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279. [Abstract]

Olanzapine (Ola: 1.0 mg/kg). The expression level of GLP-1 protein in small intestinal tissue was detected by Western blot analysis.

Olanzapine purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279. [Abstract]

Olanzapine (Ola: 1.0 mg/kg). GLP-1 immunohistochemical staining was performed on paraffin sections of the small intestine.

Olanzapine purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279. [Abstract]

Olanzapine (Ola: 1.0 mg/kg). The mRNA expression level in liver tissue was detected using real-time quantitative PCR.
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Brain Pathol

DCC in the cerebral cortex is required for cognitive functions in mouse. [Abstract]

2024 Sep 18:e13306. PMID: 39293934
Front Pharmacol

Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine. [Abstract]

2022 Aug 12:13:935362. PMID: 36034782
ACS Omega

Involvement of Integrated Stress Response in Drug-Induced Secondary Dystonia. [Abstract]

2025 Oct 17;10(42):50208-50217. PMID: 41179162
Drug Dev Res

SEP-363856 exerts neuroprotection through the PI3K/AKT/GSK-3β signaling pathway in a dual-hit neurodevelopmental model of schizophrenia-like mice. [Abstract]

2024 Jun;85(4):e22225. PMID: 38879781
Toxicol Appl Pharmacol

Paeoniflorin attenuates hyperprolactinemia by targeting the pituitary mPRα-mediated, dopamine receptor-independent signaling in vivo and in vitro. [Abstract]

2025 Sep 10:505:117551. PMID: 40939721
Patent

US20250295610A1.
University of South Carolina

2025.
Research Square Print

2022 Aug.
medRxiv

2021 Mar 1.
bioRxiv

2021 Mar 02.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (64.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2006 mL

16.0030 mL

32.0059 mL

5 mM

0.6401 mL

3.2006 mL

6.4012 mL

10 mM

0.3201 mL

1.6003 mL

3.2006 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. APPROVED AGREED-UPON LABELING.

[2]. Olanzapine for Injection, powder, for solution for intramuscular use.

[3]. Vucicevic L, et al. Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. Autophagy. 2014;10(12):2362-78. [Content Brief]

[4]. Karpel-Massler G, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. J Neurooncol. 2015 Mar;122(1):21-33. [Content Brief]

[5]. Coccurello R, et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mousemodel of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl). 2006 Jul;186(4):561-71. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2006 mL	16.0030 mL	32.0059 mL	80.0149 mL
	5 mM	0.6401 mL	3.2006 mL	6.4012 mL	16.0030 mL
	10 mM	0.3201 mL	1.6003 mL	3.2006 mL	8.0015 mL
	15 mM	0.2134 mL	1.0669 mL	2.1337 mL	5.3343 mL
	20 mM	0.1600 mL	0.8001 mL	1.6003 mL	4.0007 mL
	25 mM	0.1280 mL	0.6401 mL	1.2802 mL	3.2006 mL
	30 mM	0.1067 mL	0.5334 mL	1.0669 mL	2.6672 mL
	40 mM	0.0800 mL	0.4001 mL	0.8001 mL	2.0004 mL
	50 mM	0.0640 mL	0.3201 mL	0.6401 mL	1.6003 mL
	60 mM	0.0533 mL	0.2667 mL	0.5334 mL	1.3336 mL

Olanzapine

14 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Olanzapine

Anti-Infection Compound Library

Apoptosis Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

EMA-Approved Drug Library

5-HT Receptor Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Dopamine Receptor Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Olanzapine

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen

Alle mAChR Isoform-spezifische Produkte anzeigen

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (14)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Olanzapine Related Classifications

Art. -Nr.: HY-14541